ARCHIVES

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

This article is from The Cancer Letter archive.

Vol. 30 No. 19 | May 7, 2004

Download PDF Visit The Full Archive

Related Articles

FY’78 Construction Requests $44 Million, Budget At $12 Million

December 2, 1977

In Brief: OSCC Staff Appointments Announced Report Available On Chemical Disposal Health Aspects

August 3, 1984

NCI Advisory Group, Other Cancer Meetings

January 2, 1981

Caryn Lerman Recruited By Univ. Of Pennsylvania.

September 28, 2001

NIH Defends NCI Sponsored Travel

December 3, 2010

ELM’s CHOP-DS Aims For 15% Of Patients

September 13, 1985